Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nanfang Hospital, Southern Medical University
With
Beijing 302 Hospital
Beijing Shijitan Hospital, Capital Medical University
This is a prospective, multi-center trial conducted at 1 Guangzhou (Nanfang Hospital) and 2 Beijing (Beijing 302 Hospital, Beijing Shijitan Hospital) centers designed to determine the diagnostic performance of vHVPG (investigational technology) by anatomic CTA for non-invasive assessment of the CSPH in patients with compensated cirrhosis. Direct HVPG measurement by means of catheterization of a hepatic vein with a balloon catheter is the gold-standard method to assess the presence of CSPH, which is defined as HVPG≥10 mmHg.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \>18 years
Patients providing written informed consent
Patients with compensated cirrhosis and scheduled to undergo clinically-indicated invasive HVPG measurement by means of catheterization of a hepatic vein with a balloon catheter
Has undergone \> 64 multi-detector row CTA within 14 days prior to hepatic vein catheterization
No hepatic-portal vein interventional therapy between the CTA and hepatic vein catheterization
You may not be if
Prior transjugular intrahepatic portosystem stent-shunt surgery
Prior devascularization operation
Has received a liver transplant
Patients with known anaphylactic allergy to iodinated contrast